Purpose To explore the utility of the BRAF V600E mutation in combination with Chinese Thyroid Imaging Reporting and Data System (C-TIRADS) in the management of atypia of undetermined signi cance/follicular lesion of undetermined signi cance (AUS/FLUS) thyroid nodule (TN).Methods 138 AUS/FLUS TNs in 129 patients were included. Each TN underwent preoperative BRAF V600E mutation analysis and was classi ed using the C-TIRADS. Histopathologic diagnosis served as reference standard.Results 46 benign TNs and 92 malignant TNs were identi ed. Malignant TNs were more commonly observed in TNs with a size less than 10mm (P = 0.033). There were signi cant differences in malignancy rate among the different C-TIRADS TNs (P = 0.000), and these TNs with higher C-TIRADS were associated with increased malignancy rate (P for trend = 0.000). The rate of nodule with BRAF V600E mutation increased with the increase of C-TIRADS (P for trend = 0.001). For AUS/FLUS TNs without BRAF V600E mutation, the malignancy rates of the C-TIRADS 3, 4A, 4B, 4C, and 5 were 0%, 21.4%, 20.8%, 70.8%, and 100%, respectively (P = 0.000), and the malignancy rate increased from C-TIRADS 3 to C-TIRADS 5 (P for trend = 0.000). The diagnostic performance of C-TIRADS was similar to the BRAF V600E mutation (P > 0.05), and the sensitivity, negative predictive value, and accuracy of the combination were signi cantly higher than BRAF V600E gene or C-TIRADS alone (P < 0.05).Conclusions C-TIRADS can effectively provide risk strati cation for AUS/FLUS TNs. The combination can be helpful in selecting appropriate management for AUS/FLUS patients.
Purpose To explore the utility of the BRAFV600E mutation in combination with Chinese Thyroid Imaging Reporting and Data System (C-TIRADS) in the management of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) thyroid nodule (TN).Methods 138 AUS/FLUS TNs in 129 patients were included. Each TN underwent preoperative BRAFV600E mutation analysis and was classified using the C-TIRADS. Histopathologic diagnosis served as reference standard.Results 46 benign TNs and 92 malignant TNs were identified. Malignant TNs were more commonly observed in TNs with a size less than 10mm (P = 0.033). There were significant differences in malignancy rate among the different C-TIRADS TNs (P = 0.000), and these TNs with higher C-TIRADS were associated with increased malignancy rate (P for trend = 0.000). The rate of nodule with BRAFV600E mutation increased with the increase of C-TIRADS (P for trend = 0.001). For AUS/FLUS TNs without BRAFV600E mutation, the malignancy rates of the C-TIRADS 3, 4A, 4B, 4C, and 5 were 0%, 21.4%, 20.8%, 70.8%, and 100%, respectively (P = 0.000), and the malignancy rate increased from C-TIRADS 3 to C-TIRADS 5 (P for trend = 0.000). The diagnostic performance of C-TIRADS was similar to the BRAFV600E mutation (P > 0.05), and the sensitivity, negative predictive value, and accuracy of the combination were significantly higher than BRAFV600E gene or C-TIRADS alone (P < 0.05).Conclusions C-TIRADS can effectively provide risk stratification for AUS/FLUS TNs. The combination can be helpful in selecting appropriate management for AUS/FLUS patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.